Skip to main content
. 2025 Jan 24;111(3):2578–2589. doi: 10.1097/JS9.0000000000002238

Table 6.

Top 10 most cited articles

Rank Co-cited reference Co-citation
1 Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. 126
2 Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease. 96
3 Infliximab for the treatment of fistulas in patients with Crohn’s disease. 65
4 Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn’s Disease. 63
5 A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. 54
6 Infliximab maintenance therapy for fistulizing Crohn’s disease. 52
7 Modern management of perianal fistulas in Crohn’s disease: future directions. 51
8 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations. 50
9 Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. 50
10 Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. 43